1

Discussion & Questions From The Audience

 

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

 

Timing Question
00:00:00
  1. For recurrent desmoids or non-resectable desmoid tumors, do you like to see sorafenib as a first line or do you like to see chemotherapy as a first line?
00:05:00
  1. How do we monitor the neurocognitive effects of Avapritinib?
00:07:02
  1. For retroperitoneal, dedifferentiated liposarcoma, how long does the disease-free interval have to be to propose reoperating at the time of recurrence?
00:09:03
  1. How do you like to image such dedifferentiated liposarcomas to plan a surgical resection? Is it CT, is it MRI, is it some combination? Do you ever use FDG-PET?

 

Click Here To Watch The Video

Click Here To Open Transcript




Q&A: Catching Up On Key Concepts

 

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

 

Timing Question
00:01:15
  1. After STRASS 1, the preoperative versus no preoperative radiotherapy for primary retroperitoneal sarcoma, the first-line treatment per the results of this trial is
00:04:30
  1. According to the global, Europe, Asia, America, Consensus-Based Guideline 2020 for desmoid fibromatosis, the first-line strategy of managing a desmoid, apart from any patient with a complication is?
00:07:25
  1. What is the main clinical feature of BCOR rearranged sarcomas?
00:09:33
  1. What of the following statements is correct (with reference to WHO classification)?
00:12:55
  1. Avapritinib was approved in 2020 for what type of sarcoma?
00:14:27
  1. Which of the following is false about NTRK fusions?

 

Click Here To Watch The Video

Click Here To Open Transcript




Part 4: Through The Oncologist’s Eyes – George Demetri

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

Click Here To Watch The Video
Click Here To Open Transcript




Part 3: What The Pathologist Focusses On – Angelo Paolo Dei Tos

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

Click Here To Watch The Video
Click Here To Open Transcript




Part 2: From The Surgeon’s Point Of View – Sylvie Bonvalot

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

Click Here To Watch The Video
Click Here To Open Transcript




Part 1: Welcome & Introduction – George Demetri

The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only.

Click Here To Watch The Video
Click Here To Open Transcript